Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals ... with other cancer treatments in patients with relapsed/refractory (R/R) multiple myeloma (MM). Results presented that linvoseltamab in combination with ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our ... with relapsed/refractory (“R/R”) multiple myeloma (“MM”); the likelihood, timing ...

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

and Pfizer’s Elrexfio (elranatamab), which have both been cleared by the FDA for relapsed or refractory multiple myeloma. The top-line efficacy data with Regeneron’s drug looks a little ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for adults with relapsed and refractory multiple myeloma. This approval ...

The Food and Drug Administration is reviewing the biologics licence application for the antibody in the US, with a decision expected by 10 July 2025. Regeneron Pharmaceuticals president ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) has been granted conditional marketing approval by the European Commission (EC) to treat relapsed and refractory (R/R) multiple myeloma (MM).